Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.

You may also be interested in...



GlaxoSmithKline

NicoDerm CQ transdermal patch marketer signs development/commercialization deal with Taisho Pharmaceutical for OTC smoking cessation products in Japan. GSK will supply products, while Taisho will handle sales, distribution. Agreement comes on heels of Japan Ministry of Health's June 20 approval of Pharmacia's Nicorette gum as first OTC smoking cessation aid (1"The Tan Sheet" July 2, In Brief)

GlaxoSmithKline Abreva $10 Mil. Sales Help Offset Smoking Cessation Woes

GlaxoSmithKline's Abreva posted $10 mil. in sales during the OTC cold sore medication's first full quarter on the U.S. market.

Generic Nicotine Replacement Products Start To Smoke In 2000

Private label OTC smoking cessation products thrived in 2000, their first full year on the food, drug and mass market, recording sales well over $100 mil. and capturing nearly a 20% dollar share, according to data from Information Resources, Inc. (Chicago).

Related Content

Topics

UsernamePublicRestriction

Register

PS092837

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel